论文部分内容阅读
目的:观察沙利度胺治疗中晚期非小细胞肺癌患者的预后情况。方法:沙利度胺治疗组选取30例中晚期非小细胞肺癌患者入组研究,给予沙利度胺联合PCDE方案治疗;同时选取37例中晚期非小细胞肺癌患者作为对照组,仅使用PCDE方案治疗,分析两组患者生存率的差异。结果:沙利度胺联合PCDE方案治疗组非小细胞肺癌患者的生存率明显高于PCDE方案治疗组患者(P<0.01)。结论:采用沙利度胺联合PCDE方案治疗中晚期非小细胞肺癌,可以提高非小细胞肺癌患者的生存率,值得临床推广。
Objective: To observe the prognosis of patients with advanced non-small cell lung cancer treated with thalidomide. Methods: Thalidomide-treated patients were enrolled in the study of 30 patients with advanced non-small cell lung cancer and treated with thalidomide combined with PCDE. Meanwhile, 37 patients with advanced non-small cell lung cancer were selected as the control group and only PCDE Program treatment, analysis of differences in survival rates between the two groups. Results: The survival rate of patients with non-small cell lung cancer treated with thalidomide combined with PCDE was significantly higher than that of patients treated with PCDE (P <0.01). Conclusion: Thalidomide combined with PCDE regimen in the treatment of advanced non-small cell lung cancer, can improve the survival rate of patients with non-small cell lung cancer, deserved clinical promotion.